[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Global Molecular Diagnostics Point of Care Market: Focus on Application, Technology, Type, End User, Country Data (15 Countries), and Competitive Landscape – Analysis and Forecast, 2019-2029

September 2019 | 238 pages | ID: GD5C565391D6EN
BIS Research Inc.

US$ 4,250.00 US$ 5,000.00 -15 %
Offer valid until December 31, 2020!

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
Key Questions Answered in this Report:
  • What are the major market drivers, challenges, and opportunities in the global molecular diagnostic point of care market?
  • What are the factors resulting in the emerging trends within the global molecular diagnostic point of care market?
  • How is each segment of the global molecular diagnostic point of care market expected to grow during the forecast period and what is the estimated revenue to be generated by each of the segments by the end of 2029?
  • What is the expected compound growth rate to be witnessed by the leading players in the market during the forecast period 2019-2029?
  • What are the key applications in the global molecular diagnostic point of care market? What are the major segments of these applications?
  • Who are the key manufacturers the global molecular diagnostic point of care products, and what are their contributions?
Global Molecular Diagnostic Point of Care Market Forecast, 2019-2029

The global molecular diagnostic point of care industry analysis by BIS Research projects the market to grow at a significant CAGR of 12.14% during the forecast period, 2019-2029. The molecular diagnostic point of care market generated $1,689.6 million revenue in 2018, in terms of value.

The molecular diagnostic point of care market growth has been primarily attributed to the major drivers in this market such as highly increasing global prevalence of infectious diseases and various types of cancer, growing demand for non-invasive diagnostics, increase in adoption of personalized medicines on a global level, and significant external funding for executing research and development exercises. The challenges include an uncertain reimbursement scenario, a lack of high-complexity testing centers, and high capital requirement hampering the global reach.

Expert Quote

“There is no doubt that near-patient molecular testing represents the future of diagnosing infectious diseases, especially those like influenza that are highly transmissible.”

Scope of the Market Intelligence on Global Molecular Diagnostic Point of Care Market

The molecular diagnostic point of care research provides a holistic view of the market in terms of various factors influencing it, including regulatory reforms, and technological advancements.

The scope of this report is centered upon conducting a detailed study of the products and manufacturers allied with the diagnostic market. In addition, the study also includes exhaustive information on the unmet needs, perception on the new products, competitive landscape, market share of leading manufacturers, growth potential of each underlying sub-segment, and company, as well as other vital information with respect to global molecular diagnostic point of care market.

Market Segmentation

The molecular diagnostic point of care market is segmented into infectious disease, oncology, prenatal testing and other applications, on the basis of application.

The molecular diagnostic point of care market is segmented into polymerase chain reaction, isothermal nucleic acid amplification technology and other methods, on the basis of technology.

The molecular diagnostic point of care market is segmented into assays, systems and software, on the basis of type.

The molecular diagnostic point of care market is segmented into hospitals, clinics, diagnostic centers, and other end-users, on the basis of end-user.

The molecular diagnostic point of care market is segmented into North America, Europe, Asia-Pacific, Latin America and Rest-of-the-World, on the basis of geography.

Key Companies in the Molecular Diagnostic Point of Care Market

The key manufacturers who have been contributing significantly to the molecular diagnostic point of care market include Hologic, Inc., Abbott Laboratories, bioMerieux S.A., QIAGEN N.V., Quidel Corporation, Biocartis NV, Danaher Corporation, DiaSorin S.p.A., F. Hoffman-La Roche Ltd., Luminex Corporation, Mesa Biotech, QuantuMDx Group Ltd., Spartan Biosciences Inc., DxNA LLC, and Abacus Diagnostica Oy, among others.
EXECUTIVE SUMMARY

1 RESEARCH SCOPE AND METHODOLOGY

1.1 Scope of the Study
1.2 Research Methodology
1.3 Data Sources
1.4 Assumptions and Limitations
1.5 Data and Prediction Modeling

2 MARKET OVERVIEW

2.1 Market Available Molecular Diagnostics Point of Care Products
2.2 Molecular Diagnostics Point of Care in Clinical Diagnostics
2.3 Molecular Diagnostics Point of Care Technologies
2.4 Regulatory Framework
  2.4.1 Legal Requirements and Framework in U.S.
  2.4.2 Legal Requirements and Framework in Europe
  2.4.3 Legal Requirements and Framework in Asia-Pacific
    2.4.3.1 China
    2.4.3.2 Japan

3 MARKET DYNAMICS

3.1 Overview
3.2 Impact Analysis
3.3 Market Drivers
  3.3.1 Growing Demand for Non-Invasive Diagnosis
  3.3.2 Increasing Prevalence of Infectious Diseases and Various Types of Cancer on a Global Level
  3.3.3 Increase in Adoption of Personalized Medicine Shifting the Paradigm from Reaction to Prevention on a Global Level
  3.3.4 Significant External Funding for Executing Research and Development Exercises
3.4 Market Restraint
  3.4.1 Uncertain Reimbursement Scenario
  3.4.2 Lack of High Complexity Testing Centers
  3.4.3 High Capital Requirement Hampering the Expansion of Global Reach
3.5 Market Opportunities
  3.5.1 Massive Scope for Adoption of Molecular Diagnostics-Based Point of Care Products in Emerging Nations
  3.5.2 Technological Advancements in Molecular Techniques and Diagnostic Tests
  3.5.3 Hybridization of Technologies

4 COMPETITIVE LANDSCAPE

4.1 Key Strategies and Developments
  4.1.1 Approvals
  4.1.2 Synergistic Activities
  4.1.3 Product Launches and Enhancements
  4.1.4 Funding and Expansion Activities
  4.1.5 Acquisitions

5 GLOBAL MOLECULAR DIAGNOSTICS POINT OF CARE MARKET (BY PRODUCT)

5.1 Overview
5.2 Assays
5.3 Systems
5.4 Software

6 GLOBAL MOLECULAR DIAGNOSTICS POINT OF CARE MARKET (BY APPLICATION)

6.1 Overview
6.2 Infectious Disease
  6.2.1 Respiratory Infection
  6.2.2 Hospital Acquired Infections (HAI)
  6.2.3 Sexually Transmitted Infections (STIs)
  6.2.4 Gastro-Intestinal Infections
6.3 Oncology
6.4 Pre-natal Testing
6.5 Others

7 GLOBAL MOLECULAR DIAGNOSTICS POINT OF CARE MARKET (BY TECHNOLOGY)

7.1 Overview
7.2 Polymerase Chain Reaction (PCR)
  7.2.1 Real-time PCR (q-PCR)
  7.2.2 Digital PCR (d-PCR)
7.3 Isothermal Nucleic Acid Amplification Technology (INAAT)
7.4 Others

8 GLOBAL MOLECULAR DIAGNOSTICS POINT OF CARE MARKET (BY REGION)

8.1 Overview
8.2 North America
  8.2.1 U.S.
  8.2.2 Canada
8.3 Europe
  8.3.1 Germany
  8.3.2 U.K.
  8.3.3 France
  8.3.4 Italy
  8.3.5 Spain
  8.3.6 The Netherlands
  8.3.7 Rest-of-Europe
8.4 Asia-Pacific
  8.4.1 China
  8.4.2 Japan
  8.4.3 India
  8.4.4 Australia
  8.4.5 Singapore
  8.4.6 Rest-of-APAC
8.5 Latin America
  8.5.1 Brazil
  8.5.2 Mexico
  8.5.3 Rest-of-Latin America
8.6 Rest-of-the-World

9 GLOBAL MOLECULAR DIAGNOSTICS POINT OF CARE MARKET (BY END-USER)

9.1 Overview
9.2 Hospitals
9.3 Clinics
9.4 Diagnostic Centers
9.5 Other End-Users

10 INDUSTRY INSIGHTS

10.1 Market Share Analysis
10.2 Growth Share Analysis

11 COMPANY PROFILES

11.1 Abbott Laboratories
  11.1.1 Company Overview
  11.1.2 Role of Abbott Laboratories in the Global Molecular Diagnostics Point of Care Market
  11.1.3 Financials
  11.1.4 Key Insights about Financial Health of the Company
  11.1.5 SWOT Analysis
11.2 Abacus Diagnostica Oy
  11.2.1 Company Overview
  11.2.2 Role of Abacus Diagnostica Oy in the Global Molecular Diagnostics Point of Care Market
  11.2.3 SWOT Analysis
11.3 bioM?rieux S.A.
  11.3.1 Company Overview
  11.3.2 Role of bioM?rieux S.A. in the Global Molecular Diagnostics Point of Care Market
  11.3.3 Financials
  11.3.4 Key Insights about Financial Health of the Company
  11.3.5 SWOT Analysis
11.4 Biocartis NV
  11.4.1 Company Overview
  11.4.2 Role of Biocartis NV in the Global Molecular Diagnostics Point of Care Market
  11.4.3 Financials
  11.4.4 Key Insights about Financial Health of the Company
  11.4.5 SWOT Analysis
11.5 Danaher Corporation
  11.5.1 Company Overview
  11.5.2 Role of Danaher Corporation in the Global Molecular Diagnostics Point of Care Market
  11.5.3 Financials
  11.5.4 Key Insights about Financial Health of the Company
  11.5.5 SWOT Analysis
11.6 DiaSorin S.p.A
  11.6.1 Company Overview
  11.6.2 Role of DiaSorin S.p.A. in the Global Molecular Diagnostics Point of Care Market
  11.6.3 Financials
  11.6.4 Key Insights about Financial Health of the Company
  11.6.5 SWOT Analysis
11.7 DxNA LLC
  11.7.1 Company Overview
  11.7.2 Role of DxNA LLC in the Point of Care Global Molecular Diagnostics Point of Care Market
  11.7.3 SWOT Analysis
11.8 F. Hoffmann-La Roche Ltd
  11.8.1 Company Overview
  11.8.2 Role of F. Hoffmann-La Roche Ltd in the Global Molecular Diagnostics Point of Care Market
  11.8.3 Financials
  11.8.4 Key Insights about Financial Health of the Company
  11.8.5 SWOT Analysis
11.9 Luminex Corporation
  11.9.1 Company Overview
  11.9.2 Role of Luminex Corporation in the Global Molecular Diagnostics Point of Care Market
  11.9.3 Financials
  11.9.4 Key Insights about Financial Health of the Company
  11.9.5 SWOT Analysis
11.10 Hologic, Inc.
  11.10.1 Company Overview
  11.10.2 Role of Hologic, Inc. in the Molecular Diagnostic Point of Care Market
  11.10.3 Financials
  11.10.4 Key Insights about Financial Health of the Company
  11.10.5 SWOT Analysis
11.11 Mesa Biotech
  11.11.1 Company Overview
  11.11.2 Role of Mesa Biotech in the Molecular Diagnostics Point of Care Market
  11.11.3 SWOT Analysis
11.12 Spartan Biosciences Inc.
  11.12.1 Company Overview
  11.12.2 Role of Spartan Biosciences Inc. in the Molecular Diagnostics Point of Care Market
  11.12.3 SWOT Analysis
11.13 QuantuMDx Group Ltd.
  11.13.1 Company Overview
  11.13.2 Role of QuantuMDx Group Ltd. in the Global Molecular Diagnostics Point of Care Market
  11.13.3 SWOT Analysis
11.14 Quidel Corporation
  11.14.1 Company Overview
  11.14.2 Role of Quidel Corporation the Global Molecular Diagnostics Point of Care Market
  11.14.3 Financials
  11.14.4 Key Insights about Financial Health of the Company
  11.14.5 SWOT Analysis
11.15 QIAGEN N.V.
  11.15.1 Company Overview
  11.15.2 Role of QIAGEN N.V. in the Global Molecular Diagnostics Point of Care Market
  11.15.3 Financials
  11.15.4 Key Insights about Financial Health of the Company
  11.15.5 SWOT Analysis

LIST OF TABLES

Table 2.1: Market Available Molecular Diagnostics Point of Care Products
Table 2.2: Classification rules of IVDs under the IVDR
Table 2.3: Registration Criteria for IVD Medical Devices as per the CFDA
Table 3.1: Impact Analysis of Market Drivers
Table 3.2: Impact Analysis of Market Restraints
Table 6.1: Global Estimates of New Cases of Curable STIs in 2016

LIST OF FIGURES

Figure 1: Impact of Market Drivers and Market Restraints on the Global Molecular Diagnostics Point of Care Market
Figure 2: Global Molecular Diagnostics Point of Care Market Snapshot, 2018 and 2029
Figure 3: Dominating Segments of the Global Molecular Diagnostics Point of Care Market, 2019 and 2029
Figure 4: Key Strategies Incorporated by Stakeholders of Molecular Diagnostics Point of Care Market, to Sustain the Competition (from January 2016 to August 2019)
Figure 5: Global Molecular Diagnostics Point of Care Market Point of Care (by Product), 2018 and 2029
Figure 6: Global Molecular Diagnostics Point of Care Market (by Technology), 2018 and 2029
Figure 7: Global Molecular Diagnostics Point of Care Market (by End-User), 2018 and 2029
Figure 8: Global Molecular Diagnostics Point of Care Market (by Region) 2018 and 2029
Figure 1.1: Global Molecular Diagnostics Point-of-Care Market Segmentation
Figure 1.2: Global Molecular Diagnostics Point of Care Market Research Methodology
Figure 1.3: Primary Research
Figure 1.4: Secondary Research
Figure 1.5: Data Triangulation
Figure 1.6: Bottom-Up Approach (Segment-Wise Analysis)
Figure 1.7: Top-Down Approach (Segment-Wise Analysis)
Figure 1.8: Assumptions and Limitations
Figure 1.9: Considered Factors for Data Prediction and Modeling
Figure 2.1: Characteristics of a Commercially Available Molecular Diagnostics Point of Care Products
Figure 2.2: Components Considered for Clinical Evidence as per the IVDR
Figure 3.1: Number of Deaths due to top 18 Infectious Diseases on a Global Scale, 2015
Figure 3.2: Number of Deaths due to Different Forms of Cancer, Million Units, 2018,
Figure 4.1: Share of Key Developments and Strategies, January 2016 – August 2019
Figure 4.2: Approvals Share (by Company), January 2016 – August 2019
Figure 4.3: Synergistic Activities Share (by Company), January 2016 – August 2019
Figure 4.4: Product Launches and Enhancements Share (by Company), January 2016 – August 2019
Figure 4.5: Funding Share (by Company), January 2016 – August 2019
Figure 4.6: Acquisitions Share (by Company), January 2016 – August 2019
Figure 5.1: Global Molecular Diagnostics Point of Care Market (by Product)
Figure 5.2: Global Molecular Diagnostics Point of Care Market (by Product), 2018-2029
Figure 5.3: General Workflow of a Molecular Diagnostics Point of Care Kit
Figure 5.4: Global Molecular Diagnostics Point of Care Market (Assays), 2018-2029
Figure 5.5: Global Molecular Diagnostics Point of Care Market (by Systems), 2018-2029
Figure 5.7: Aspects of Software Development
Figure 5.8: Global Molecular Diagnostics Point of Care Market (by Software), 2018-2029
Figure 6.1: Global Molecular Diagnostics Point of Care Market (by Application), 2018-2029
Figure 6.2: Global Molecular Diagnostics Point of Care Market (by Infectious Disease), 2018-2029
Figure 6.3: Global Molecular Diagnostics Point of Care Market (by Infectious Disease Type), 2018-2020
Figure 6.4: Global Molecular Diagnostics Point of Care Market (by Respiratory Infections), 2018-2029
Figure 6.5: Global Molecular Diagnostics Point of Care Market (by Hospital Acquired Infections), 2018-2029
Figure 6.6: Global Molecular Diagnostics Point of Care Market (by Sexually Transmitted Infections), 2018-2029
Figure 6.7: Global Molecular Diagnostics Point of Care Market (by Gastro-Intestinal Infections), 2018-2029
Figure 6.8: Global Molecular Diagnostics Point of Care Market (by Oncology), 2018-2029
Figure 6.9: Global Molecular Diagnostics Point of Care Market (by Pre-natal Testing), 2018-2029
Figure 6.10: Global Molecular Diagnostics Point of Care Market (by Other Applications), 2018-2029
Figure 7.1: Global Molecular Diagnostics Point of Care Market (by Technology), 2018-2029
Figure 7.2: Global Molecular Diagnostics Point of Care Market (by PCR), 2018-2029
Figure 7.3: Global Molecular Diagnostics Point of Care Market (by q-PCR), 2018-2029
Figure 7.4: Global Molecular Diagnostics Point of Care Market (by d-PCR), 2020-2029
Figure 7.5: Global Molecular Diagnostics Point of Care Market (by INAAT), 2018-2029
Figure 7.6: Global Molecular Diagnostics Point of Care Market (by Other Technologies), 2018-2029
Figure 8.1: Global Molecular Diagnostics Point of Care Market (by Region), 2018 and 2029
Figure 8.2: Global Molecular Diagnostics Point of Care Market Point of Care (by Region), 2018-2029
Figure 8.3: Global Molecular Diagnostics Point of Care Market Share (by Region), 2018
Figure 8.4: Global Molecular Diagnostics Point of Care Market Share (by Region), 2029
Figure 8.5: North America Molecular Diagnostics Point of Care Market, 2018-2029
Figure 8.6: North America Molecular Diagnostics Point of Care Market (by Country), 2018-2029
Figure 8.7: North America: Market Dynamics
Figure 8.8: The U.S. Molecular Diagnostics Point of Care Market, 2018-2029
Figure 8.9: Canada Molecular Diagnostics Point of Care Market, 2018-2029
Figure 8.10: Overview of Reimbursement Policies in Europe (Focus on Companion Diagnostics as well)
Figure 8.11: Europe Molecular Diagnostics Point of Care Market, 2018-2029
Figure 8.12: Europe: Market Dynamics
Figure 8.13: Europe Molecular Diagnostics Point of Care Market (by Country), 2018-2029
Figure 8.14: Germany Point of Care Molecular Diagnostics Market, 2018-2029
Figure 8.15: U.K. Molecular Diagnostics Point of Care Market, 2018-2029
Figure 8.16: France Molecular Diagnostics Point of Care Market, 2018-2029
Figure 8.17: Italy Molecular Diagnostics Point of Care Market, 2018-2029
Figure 8 18: Spain Molecular Diagnostics Point of Care Market, 2018-2029
Figure 8.19: The Netherlands Molecular Diagnostics Point of Care Market, 2018-2029
Figure 8.20: Rest-of-Europe Molecular Diagnostics Point of Care Market, 2018-2029
Figure 8.21: Asia-Pacific Molecular Diagnostics Point of Care Market, 2018-2029
Figure 8.22: APAC: Market Dynamics
Figure 8.23: APAC Global Molecular Diagnostics Point of Care Market (by Country), 2018-2029
Figure 8.24: China Molecular Diagnostics Point of Care Market, 2018-2029
Figure 8.25: Japan Molecular Diagnostics Point of Care Market, 2018-2029
Figure 8.26: India Molecular Diagnostics Point of Care Market, 2018-2029
Figure 8.27: Australia Molecular Diagnostics Point of Care Market, 2018-2029
Figure 8.28: Singapore Molecular Diagnostics Point of Care Market, 2018-2029
Figure 8.29: RoAPAC Molecular Diagnostics Point of Care Market, 2018-2029
Figure 8.30: Latin America Molecular Diagnostics Point of Care Market, 2018-2029
Figure 8.31: Latin America: Market Dynamics
Figure 8.32: Latin America Molecular Diagnostics Point of Care Market (by Country), 2018-2029
Figure 8.33: Brazil Molecular Diagnostics Point of Care Market 2018-2029
Figure 8.34: Mexico Molecular Diagnostics Point of Care Market, 2018-2029
Figure 8.35: Rest-of-Latin America Molecular Diagnostics Point of Care Market, 2018-2029
Figure 8.36: RoW Molecular Diagnostics Point of Care Market, 2018-2029
Figure 9.1: Global Molecular Diagnostics Point of Care Market (by End-User)
Figure 9.2: Global Molecular Diagnostics Point of Care Market (by End User), 2018-2029
Figure 9.3: Global Molecular Diagnostics Point of Care Market (by Hospitals), 2018-2029
Figure 9.4: Global Molecular Diagnostics Point of Care Market (by Clinics), 2018-2029
Figure 9.5: Global Molecular Diagnostics Point of Care Market (Diagnostic Centers), 2018-2029
Figure 9.6: Global Molecular Diagnostics Point of Care Market (by Other End-Users), 2018-2029
Figure 10.1: Market Share Analysis for the Global Molecular Diagnostics Point of Care Market, 2018
Figure 10.2: Growth Share Matrix for Molecular Diagnostics Point of Care Market (by Company), 2018
Figure 11.1: Total Number of Companies Profiled
Figure 11.2: Abbott Laboratories: Overall Product Portfolio
Figure 11.3: Abbott Laboratories: Overall Financials, 2016-2018
Figure 11.4: Abbott Laboratories: Revenue (by Segment), 2016-2018
Figure 11.5: Abbott Laboratories: Revenue Split for Diagnostics, 2016-2018
Figure 11.6: Abbott Laboratories: Revenue (by Region), 2016-2018
Figure 11.7: Abbott Laboratories: R&D Expenditure, 2016-2018
Figure 11.8: Abbott Laboratories: SWOT Analysis
Figure 11.9: Abacus Diagnostica Oy.: Overall Product Portfolio (Available from FY2019)
Figure 11.10: Abacus Diagnostica Oy: SWOT Analysis
Figure 11.11: bioM?rieux S.A.: Overall Product Portfolio
Figure 11.12: bioM?rieux S.A.: Overall Financials, 2016-2018
Figure 11.13: bioM?rieux S.A.: Revenue (by Segment), 2016-2018
Figure 11.14: bioM?rieux S.A.: Revenue (by Region), 2016-2018
Figure 11.15: bioM?rieux S.A.: R&D Expenditure, 2016-2018
Figure 11.16: bioM?rieux S.A.: SWOT Analysis
Figure 11.17: Biocartis NV: Overall Product Portfolio
Figure 11.18: Biocartis NV: Overall Financials, 2016-2018
Figure 11.19: Biocartis NV: R&D Expenditure, 2016-2018
Figure 11.20: Biocartis NV: SWOT Analysis
Figure 11.21: Danaher Corporation: Molecular Diagnostics Point of Care Product Portfolio
Figure 11.22: Danaher Corporation: Overall Financials, 2016-2018
Figure 11.23: Danaher Corporation: Revenue (by Business Segment), 2016-2018
Figure 11.24: Danaher Corporation: Revenue (by Region), 2016-2018
Figure 11.25: Danaher Corporation: R&D Expenditure, 2016-2018
Figure 11.26: Danaher Corporation: SWOT Analysis
Figure 11.27: DiaSorin S.p.A.: Overall Financials, 2016-2018
Figure 11.28: DiaSorin S.p.A.: Revenue (by Segment), 2016-2018
Figure 11.29: DiaSorin S.p.A.: By Region, 2016-2018
Figure 11.30: DiaSorin S.p.A: R&D Expenditure, 2016-2018
Figure 11.31: DiaSorin S.p.A: SWOT Analysis
Figure 11.32: DxNA LLC.: Overall Product Portfolio (Available from FY2019)
Figure 11.33: DxNA LLC Group Ltd.: SWOT Analysis
Figure 11.34: F. Hoffmann-La Roche Ltd: Overall Product Portfolio
Figure 11.35: F. Hoffmann-La Roche Ltd: Overall Product Portfolio
Figure 11.36: F. Hoffmann-La Roche Ltd: Overall Financials, 2016-2018
Figure 11.37: F. Hoffmann-La Roche Ltd: Revenue (by Segment), 2016-2018
Figure 11.38: F. Hoffmann-La Roche Ltd: Revenue Split for Diagnostics, 2016-2018
Figure 11.39: F. Hoffmann-La Roche Ltd: Revenue (by Region), 2016-2018
Figure 11.40: F. Hoffmann-La Roche Ltd: R&D Expenditure, 2016-2018
Figure 11.41: F. Hoffmann-La Roche Ltd: SWOT Analysis
Figure 11.42: Luminex Corporation: Overall Product Portfolio
Figure 11.43: Luminex Corporation: Overall Financials, 2016-2018
Figure 11.44: Luminex Corporation: Revenue (by Segment), 2016-2018
Figure 11.45: Luminex Corporation: Revenue (by Region), 2016-2018
Figure 11.46: Luminex Corporation: R&D Expenditure, 2016-2018
Figure 11.47: Luminex Corporation: SWOT Analysis
Figure 11.48: Hologic, Inc.: Overall Product Portfolio
Figure 11.49: Hologic, Inc.: Overall Financials, 2016-2018
Figure 11.50: Hologic, Inc.: Revenue (by Segment), 2016-2018
Figure 11.51: Hologic, Inc.: Revenue (by Region), 2016-2018
Figure 11.52: Hologic, Inc.: R&D Expenditure, 2016-2018
Figure 11.53: Hologic, Inc.: SWOT Analysis
Figure 11.54: Mesa Biotech: Overall Product Portfolio (Available from FY2019)
Figure 11.55: Mesa Biotech: SWOT Analysis
Figure 11.56: Spartan Biosciences Inc.: Overall Product Portfolio (Available from FY2019)
Figure 11.57: Spartan Biosciences, Inc.: SWOT Analysis
Figure 11.58: QuantuMDx Group Ltd.: Overall Product Portfolio (Available from FY2019)
Figure 11.59: QuantuMDx Group Ltd.: SWOT Analysis
Figure 11.60: Quidel Corporation Ltd.: Overall Product Portfolio (Available from FY2019)
Figure 11.61: Quidel Corporation: Overall Financials, 2016-2018
Figure 11.62: Quidel Corporation: Revenue (by Segment), 2016-2018
Figure 11.63: Quidel Corporation: Revenue (by Region), 2016-2018
Figure 11.64: Quidel Corporation: R&D Expenditure, 2016-2018
Figure 11.65: Quidel Corporation: SWOT Analysis
Figure 11.66: QIAGEN N.V.: Overall Product Portfolio
Figure 11.67: QIAGEN N.V.: Overall Financials, 2016-2018
Figure 11.68: QIAGEN N.V.: Revenue (by Segment), 2016-2018
Figure 11.69: QIAGEN N.V.: Revenue (by Region), 2016-2018
Figure 11.70: QIAGEN N.V.: R&D Expenditure, 2016-2018
Figure 11.71: QIAGEN N.V.: SWOT Analysis


More Publications